Femara Gets Indication for Early-Stage Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis touts a New England Journal of Medicine article stating that letrozole is superior to tamoxifen.
You may also be interested in...
Novartis’ Femara Improves Disease-Free Survival In Breast Cancer Patients Post Tamoxifen – JCO Article
Cohort analysis demonstrates treatment with letrozole one to seven years after tamoxifen therapy led to 63 percent reduction in disease recurrence.
Novartis’ Femara Improves Disease-Free Survival In Breast Cancer Patients Post Tamoxifen – JCO Article
Cohort analysis demonstrates treatment with letrozole one to seven years after tamoxifen therapy led to 63 percent reduction in disease recurrence.
Novartis Bullish About Prexige; Anticipates Blockbuster Potential
Company takes a more bullish stance on its COX-2 inhibitor than Merck, which has assumed FDA approval of its Vioxx follow-on product Arcoxia in 2007.